Molecular Partners Ag (MOLN) Asset Writedowns and Impairment (2021 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Asset Writedowns and Impairment of $14.05 for Q1 2026, down 98.88% year-on-year from $1259.1 in Q1 2025, and up 100.0% on a QoQ basis from -$5.8 million in Q3 2025.
Molecular Partners Ag (MOLN) Asset Writedowns and Impairment (2021 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Asset Writedowns and Impairment for 6 consecutive years, with $14.05 the latest figure, recorded in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.05 |
| Mar 31, 2026 | 14.05 |
| Sep 30, 2025 | -5.79 Mn |
| Sep 30, 2025 | -5.79 Mn |
| Jun 30, 2025 | 5.59 Mn |
| Jun 30, 2025 | 5.59 Mn |
| Mar 31, 2025 | 1,259.07 |
| Mar 31, 2025 | 1,259.07 |
| Sep 30, 2024 | -23,050.67 |
| Sep 30, 2024 | -23,050.67 |
| Jun 30, 2024 | 22,104.81 |
| Jun 30, 2024 | 22,104.81 |
| Mar 31, 2024 | 11.46 |
| Mar 31, 2024 | 11.46 |
| Sep 30, 2023 | -1.98 Mn |
| Sep 30, 2023 | -1.98 Mn |
| Jun 30, 2023 | 1.94 Mn |
| Jun 30, 2023 | 1.94 Mn |
| Mar 31, 2023 | 602.21 |
| Mar 31, 2023 | 602.21 |